129.97 0.00 (0.00%)
After hours: 4:43PM EDT
|Bid||129.70 x 800|
|Ask||129.89 x 800|
|Day's Range||129.51 - 130.90|
|52 Week Range||99.65 - 130.90|
|Beta (3Y Monthly)||0.58|
|PE Ratio (TTM)||14.67|
|Earnings Date||Jul 9, 2019|
|Forward Dividend & Yield||3.71 (2.90%)|
|1y Target Est||127.84|
Annual 9,000+ mile relay across the U.S. has raised more than $1 million to-date WHITE PLAINS, N.Y. , May 23, 2019 /PRNewswire/ -- Today, in advance of Memorial Day weekend, the fifth annual PepsiCo (NASDAQ:PEP) ...
Hormel Foods' (HRL) top and bottom lines grow year over year in second-quarter fiscal 2019. However, input cost inflation and expectations of volatile pork prices lead to a lowered outlook.
[Editor's note: This story was previously published in March 2019. It has since been updated and republished.]Cannabidiol (CBD) is emerging as a red-hot category of the marijuana industry. CBD consists of compounds in the cannabis sativa plant that do not produce a high. In fact, over the years, CBDs have been shown to have powerful therapeutic effects.Now it looks like the U.S. market could open up in a big way for this type of cannabis and several CBD stocks are gaining traction. The reason: In December, Congress passed the 2018 Farm Bill, which declared that CBD would no longer be treated as an illegal substance.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo how big could this opportunity be? Well, according to research from the Brightfield Group, the market in the U.S. could hit $22 billion by 2022. * 6 Stocks to Buy for This Decade's Massive Megatrend No doubt, this could move the needle for marijuana stocks -- and here's a look at seven that stand out: Marijuana Stocks Poised to Benefit From CBD Legalization: Cronos Group (CRON)Cronos Group (NYSE:CRON) operates a vertically integrated cannabis platform, with a presence across five continents. In terms of the CBD opportunity, the company recently struck a strategic partnership with Gingko Bioworks, which has raised $430 million. The company's founder, Tom Knight, is known as the "father of synthetic biology" and his innovations -- such as with software to print DNA -- should allow for the creation of cannabinoids at a massive scale. This is critical because it can be difficult to produce pure forms that are cost-effective and precise.CRON also has the advantage of substantial financial resources to commercialize its cannabinoids. Last December, Altria (NYSE:MO) invested $1.8 billion into the company for a 45% stake. The deal is certainly a validation of CRON but it will also allow for much broader distribution and improved product development.Of course, a company like MO does engage in substantial due diligence before making an investment. In the company's Q4 earnings call, CEO Howard Willard said: "We believe the growth opportunities are significant and will extend across the globe as cannabis markets open. Selecting the right partner in this category was critical and we've done just that. Cronos strong management team has built unique capabilities to compete globally across the medicinal, recreational and nutraceutical categories." Marijuana Stocks Poised to Benefit From CBD Legalization: Aurora Cannabis (ACB)Aurora Cannabis (NYSE:ACB), a Canadian based cannabis producer, has been building up its CBD business. Part of this has been with its investments in industrial hemp production, such as with the Radient facility in Edmonton. It is expected to get as much as 10,000 kilos per day.Next, ACB has been focused on revving up its product offerings. On its Q2 earnings call, Chief Corporate Officer Cam Battley said the company is poised "to launch a broad line of CBD based wellness product in the near future."What's more, ACB has been aggressive with its dealmaking. For example, it has increased its equity position in Hempco and purchased Agropro, which is Europe's largest hemp producer. * 6 Stocks to Buy for This Decade's Massive Megatrend Something else to keep in mind: Legendary billionaire investor Nelson Peltz has joined the company as an advisor. This is certainly a major vote of confidence. He not only has deep access to investment capital but a strong network of potential partners, especially in the consumer goods industry. Some of his investments include stakes in PepsiCo (NASDAQ:PEP), Procter & Gamble (NYSE:PG) and Mondelez (NASDAQ:MDLZ). Marijuana Stocks Poised to Benefit From CBD Legalization: Charlotte's Web (CWBHF)The inspiration for the founding of Charlotte's Web (OTCMKTS:CWBHF) was a CNN documentary -- in 2013 -- about Charlotte Figi, whose health was significantly improved because of a hemp extract.Fast forward to today: The company is the No. 1 brand for the hemp-derived CBD market in the U.S. It definitely helps that it has distribution across more than 3,000 retail locations.And yes, growth has been strong. In Q3, revenues jumped by 57% to $17.7 million and adjusted EBITDA came to $5.4 million, up 31%.To better capitalize on the CBD opportunity, CWBHF issued $71.5 million in stock. This will be for cultivation and production to meet surging demand. Here's what the company's CEO, Hess Moallem, had to say: "In general, broader consumer awareness of the benefits of cannabinoids, namely cannabidiol (CBD), and whole plant hemp extract is driving increased uptake in both our retail channels and within our e-commerce platform."In other words, it seems like a pretty good bet that the growth will continue for some time. Marijuana Stocks Poised to Benefit From CBD Legalization: Zynerba Pharmaceuticals (ZYNE)Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage biotech company that develops cannabinoid therapies for a variety of rare diseases. They include: * Fragile X Syndrome (FXS): This is a developmental disability that has been known to cause autism spectrum disorder. FXS impacts 71,000 people in the U.S. and there are no drug indications for it. * Developmental and Epileptic Encephalopathies (DEE): This is an epilepsy syndrome that involves severe cognitive impairment. About 45,000 children and adolescents have this in the U.S. * Autism Spectrum Disorder (ASD): This includes autism and Asperger's syndrome. ASD affects less than 1 million pediatric and adolescent patients. * 6 Stocks to Buy for This Decade's Massive Megatrend ZYNE's main candidate is Zygel, which is a CBD formulation gel for transdermal delivery. As for the FXS treatment, there is expected to be a pivotal data release in the second half of this year. And if the trial is positive, then the company will file a New Drug Application (NDA) for Zygel in the first half of 2020. Marijuana Stocks Poised to Benefit From CBD Legalization: Canopy Growth (CGC)Since 2016, Canopy Growth (NYSE:CGC) has been building its CBD business, with a focus on consumer packaged goods. The company has since created a vertically integrated platform for that includes a set of technologies that have pending patents. What's more, the hemp division is expected to yield 7,000 kilos of hemp-derived CBD on an annual basis. Granted, this cannot be used in the U.S. market. Yet CGC is likely to be a solid partner. For example, the company struck a deal with Martha Stewart's Sequential Brands Group, so as to develop CBD remedies for pets.It helps that CGC has substantial resources, which came from a mega $4 billion investment from Constellation Brands (NYSE:STZ). STZ has a strong global footprint -- with operations in the U.S., Mexico, New Zealand, Italy and Canada -- as well as a set of well-known consumer brands, such as Corona Extra, Corona Light, Modelo Especial, Modelo Negra and Pacifico. All in all, there is quite a bit of synergy for CGC.In the meantime, the company is growing at a staggering pace. In Q3, its revenues soared by 282% to $83 million. Marijuana Stocks Poised to Benefit From CBD Legalization:GW Pharmaceuticals (GWPH)The origins of GW Pharmaceuticals (NASDAQ:GWPH) go back to 1998. It was then that Dr. Geoffrey Guy and Dr. Brian Whittle co-founded the company to focus on developing therapies using cannabinoid formulations to target areas like epilepsy, glioma and schizophrenia.As of today, the lead product is a liquid formulation of a CBD, called Epidiolex, which received FDA approval in 2018 (the expectation is that there will be an approval in Europe in the second quarter). The drug targets the rare conditions of Lennox-Gastaut syndrome (LGS) or Dravet syndrome, which are variations of epilepsy. Furthermore, there are other indications for Epidiolex, such as Tuberous Sclerosis Complex and Rett Syndrome. * 6 Stocks to Buy for This Decade's Massive Megatrend But of course, the company has other treatments. Note that GWPH is looking to get approval in the U.S. for Sativex, which is an oromucosal spray for multiple sclerosis. It is currently available in 25 countries. Marijuana Stocks Poised to Benefit From CBD Legalization: Horizons Marijuana Life Sciences ETF (HMLSF)If you do not want to buy individual CBD stocks, then you can consider an exchange-traded fund, such as the Horizons Marijuana Life Sciences ETF (OTCMKTS:HMLSF). With this, you'll get exposure to companies like Canopy Growth, Aurora, GW Pharamceuticals, HEXO and Tilray (NASDAQ:TLRY).In all, there are 59 stocks in the portfolio and the net assets are about $890 million (in Canadian currency).Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 6 Stocks to Buy for This Decade's Massive Megatrend * The 7 Best Stocks to Buy From the IPO ETF * 7 Athletic Apparel Stocks With Marathon Pace Compare Brokers The post 7 Marijuana Stocks to Play the CBD Trend appeared first on InvestorPlace.
The summer season is packed with snacks. To explore just where, when and how Americans will snack this summer, Frito-Lay today unveiled the next installment of its U.S. Snack Index. As the unofficial start of summer, Memorial Day historically starts a spike and then snacking hits its highest point during the week of July 4.
Welcome to the latest episode of the Full-Court Finance podcast from Zacks Investment Research where Associate Stock Strategist Ben Rains breaks down Beyond Meat, Inc. (BYND) and its recent IPO that has seen it destroy Uber (UBER) and Lyft (LYFT).
In Collaboration with Instagram, Pepsi to Launch Hundreds of New AR Filters Tied to Summer-Themed Statements and Icons Appearing on More Than 230 Million Bottles and Cups; Reigning Social Media Royalty ...
PURCHASE, N.Y., May 20, 2019 /PRNewswire/ -- Digital disruption driven by consumer engagement with technology is transforming the restaurant and hospitality industry. That is why PepsiCo, Inc. (PEP), announced the launch of PepsiCo Foodservice Digital Lab, a first-of-its-kind suite of capabilities built to connect foodservice operators with the companies, services, insights, and solutions best suited for their specific digital and online needs. Powered by extensive proprietary and syndicated research into restaurant and food ordering interactions as part of the consumer digital journey, Digital Lab is the first offering of its kind from a foodservice manufacturer.
PepsiCo (PEP) is one of the 10 favorite stocks of Kevin O'Leary, or "Mr. Wonderful," as he is known on TV. Warning! GuruFocus has detected 3 Warning Signs with PBHC. PepsiCo is a gigantic food and beverage company, with a market capitalization of $183 billion and $66 billion in annual sales.
In this daily bar chart of PEP, below, we can see share prices have rallied nicely the past 12 months. The daily On-Balance-Volume (OBV) line has moved up to a new high since the middle of March to confirm the new price highs. In this weekly bar chart of PEP, below, we can see that prices finally broke out to new highs in late March after more than a two year consolidation pattern.
PURCHASE, N.Y. and SANTA MONICA, Calif. , May 17, 2019 /PRNewswire/ -- Pacific Park on the Santa Monica Pier has selected PepsiCo (NASDAQ: PEP) as its exclusive beverage provider forming a new multiyear ...
PepsiCo (PEP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Retail sales, industrial production, and fixed asset investment all came in well short of estimates on a year-over-year basis. On Wednesday morning, the U.S. also reported some disappointing economic news. Retail sales, which were expected to rise 0.2% in the month of April, instead fell by 0.2%.
AB InBev (BUD) is a favored stock due to strong sales trends, strength in global brands and robust outlook. However, soft earnings trend due to currency headwinds and cost inflation cannot be ignored.
Competition is heating up in the alternative-meat category. Beyond Meat competitor Impossible Foods just raised $300 million.
Shares of Coca-Cola were rising Tuesday in premarket trading after analysts at Morgan Stanley upgraded the consumer staples giant to overweight from equal weight. The stock was rising 2.36% to $49.18 a share.
As uncertainty over the outcome of Sino-American trade talks grows, so does the possibility of a longer-than-expected negotiations or an all-out trade war, strategists at Goldman Sachs are providing some timely trading strategies.
PURCHASE, N.Y. , May 13, 2019 /PRNewswire/ -- PepsiCo, Inc. (NASDAQ: PEP) today announced that it will issue its second quarter (ending June 15) financial results on Tuesday, July 9, 2019 at approximately 6:00 ...